000			02289cgm a2200481 a 4500
001			HST2040_1_2
003			UkLoHST
006			m c
007			cr|cna|||a||||
007			vz|czazum
008			181015s2018 enk|||||||||||s|||v|eng d
028	5	0	_a2040 _bHenry Stewart Talks
035			_a(UkLoHST)1117
040			_aUkLoHST _beng _cUkLoHST
100	1		_aMarkman, Maurie. _4spk
245	1	0	_aSurrogate endpoints of efficacy _h[electronic resource] / _cMaurie Markman.
260			_aLondon : _bHenry Stewart Talks, _c2018.
300			_a1 online resource (1 streaming video file (33 min.) : _bcolor, sound).
490	1		_aCancer therapy : latest thinking in efficacy and toxicity, _x2056-452X
500			_aAnimated audio-visual presentation with synchronized narration.
500			_aTitle from title frames.
500			_aUpdated version of a talk first published in 2009.
505	0		_aContents: Improvement in overall survival must be considered the single most important goal of any new antineoplastic strategy -- Also increasingly recognized that in well-defined settings it is reasonable to employ other objectively measurable endpoints of efficacy such as time to symptomatic disease progression -- The rationale for the use of surrogate or alternative endpoints in cancer clinical trials -- Examples of where such endpoints may be appropriately utilized.
506			_aAccess restricted to subscribers.
538			_aMode of access: World Wide Web.
650		0	_aAntineoplastic agents.
650		0	_aCancer _xChemotherapy.
650		0	_aCancer _xTreatment _xEvaluation.
650		0	_aClinical trials.
650		0	_aOutcome assessment (Medical care)
650		2	_aAntineoplastic Agents _xadministration & dosage.
650		2	_aAntineoplastic Agents _xtherapeutic use.
650		2	_aBiomarkers.
650		2	_aClinical Trials as Topic.
650		2	_aEndpoint Determination.
650		2	_aGoals.
650		2	_aNeoplasms _xprevention & control.
650		2	_aNeoplasms _xtherapy.
650		2	_aTreatment Outcome.
830		0	_aHenry Stewart talks. _pBiomedical & life sciences collection. _pCancer therapy : latest thinking in efficacy and toxicity.
856	4	0	_uhttps://hstalks.com/bs/1117/
856	4	2	_uhttps://hstalks.com/bs/p/385/ _3Series
999			_c76293 _d76293